Advertisement

Tumor Biology

, Volume 37, Issue 3, pp 4135–4142 | Cite as

Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer

  • Jin Hong
  • Yan Mao
  • Xiaosong Chen
  • Li Zhu
  • Jianrong He
  • Weiguo Chen
  • Yafen Li
  • Lin Lin
  • Xiaochun Fei
  • Kunwei Shen
Original Article

Abstract

Inflammation and tumor immune microenviroment are critical factors for prognosis in numerous cancers. The aim of this study was to determine the prognostic value of preoperative neutrophil-to-lymphocyte ratio (NLR) in breast cancer. We performed a retrospective analysis of 487 patients diagnosed with primary breast cancer at Shanghai Ruijin hospital from January 2009 to December 2010. Hematological parameters before surgery, clinicopathological data, and survival status were obtained. Survival analysis was used to evaluate the prognostic value of NLR. The optimal cutoff value was determined as 1.93 for NLR and the median follow-up time was 55.0 months. On univariate analysis, patients with high NLR (>1.93) had worse 5-year disease-free survival (DFS) compared to those with low NLR (77.9 vs 88.0 %, p = 0.002). Regarding overall survival, there was no significant difference between patients with high NLR and low NLR, with 5-year overall survival of 90.8 and 91.7 % (p = 0.707). In triple-negative breast cancer, patients with high NLR was associated with worse 5-year DFS compared with patients with low NLR (63.4 vs 84.9 %, p = 0.040). Mutivariate analysis revealed that NLR was an independent prognostic factor for DFS in breast cancer (HR = 1.867, 95 % confidence interval; (95%CI) = 1.155–3.017, p = 0.011). Preoperative NLR is an independent predictor of DFS in breast cancer patients, especially in triple-negative subtype. Further studies are required to validate the prognostic value of NLR before clinical application.

Keywords

Breast cancer Neutrophil-to-lymphocyte ratio Disease-free survival Molecular subtype 

Notes

Acknowledgments

We would like to thank all patients participating in our study. This research was supported by the grants from Technology Innovation Act Plan of Shanghai Municipal Science and Technology Commission (Grant Number: 14411950200, 14411950201).

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. doi: 10.3322/caac.21203.CrossRefPubMedGoogle Scholar
  2. 2.
    Fan L, Strasser-Weippl K, Li J-J, St Louis J, Finkelstein DM, Yu K-D, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. doi: 10.1016/s1470-2045(13)70567-9.CrossRefPubMedGoogle Scholar
  3. 3.
    Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812–23. doi: 10.1016/s0140-6736(11)61539-0.CrossRefPubMedGoogle Scholar
  4. 4.
    Chew V, Toh HC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:608406. doi: 10.1155/2012/608406.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99. doi: 10.1016/j.cell.2010.01.025.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950–8. doi: 10.1016/j.ejca.2009.01.023.CrossRefPubMedGoogle Scholar
  7. 7.
    Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93(3):273–8. doi: 10.1038/sj.bjc.6602702.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006;32(1):22–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Wang Y, Liu P, Xu Y, Zhang W, Tong L, Guo Z, et al. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Cancer Chemother Pharmacol. 2014. doi: 10.1007/s00280-014-2622-6.Google Scholar
  10. 10.
    Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Okamura Y. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after gastroenterostomy in patients with advanced pancreatic adenocarcinoma. Ann Surg Oncol. 2013;20(13):4330–7. doi: 10.1245/s10434-013-3227-8.CrossRefPubMedGoogle Scholar
  11. 11.
    Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;109(7):1755–9. doi: 10.1038/bjc.2013.522.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xue TC, Zhang L, Xie XY, Ge NL, Li LX, Zhang BH, et al. Prognostic significance of the neutrophil-to-lymphocyte ratio in primary liver cancer: a meta-analysis. PLoS One. 2014;9(5):e96072. doi: 10.1371/journal.pone.0096072.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403–13. doi: 10.1002/ijc.28536.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang X, Zhang W, Feng LJ. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS One. 2014;9(11):e111906. doi: 10.1371/journal.pone.0111906.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013. doi: 10.1093/annonc/mdt303.PubMedCentralGoogle Scholar
  16. 16.
    Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  17. 17.
    Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71. doi: 10.1038/nrc3611.CrossRefPubMedGoogle Scholar
  18. 18.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. doi: 10.1038/nature07205.CrossRefPubMedGoogle Scholar
  19. 19.
    Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11). doi: 10.1093/jnci/dju268.
  20. 20.
    Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259–71. doi: 10.1093/annonc/mdu450.CrossRefPubMedGoogle Scholar
  21. 21.
    Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50. doi: 10.1093/annonc/mdu112.CrossRefPubMedGoogle Scholar
  22. 22.
    Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55. doi: 10.1200/JCO.2010.30.5037.CrossRefPubMedGoogle Scholar
  23. 23.
    Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol. 2013;31(7):860–7. doi: 10.1200/JCO.2011.41.0902.CrossRefPubMedGoogle Scholar
  24. 24.
    Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, et al. Intratumoral CD8(+) cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One. 2014;9(4):e95475. doi: 10.1371/journal.pone.0095475.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of Tumor Infiltrating Lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115103. doi: 10.1371/journal.pone.0115103.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Miyashita M, Sasano H, Tamaki K, Chan M, Hirakawa H, Suzuki A, et al. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2014;148(3):525–34. doi: 10.1007/s10549-014-3197-y.CrossRefPubMedGoogle Scholar
  27. 27.
    West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402–10. doi: 10.1016/j.imbio.2013.06.003.CrossRefPubMedGoogle Scholar
  29. 29.
    Queen MM. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res. 2005;65(19):8896–904. doi: 10.1158/0008-5472.can-05-1734.CrossRefPubMedGoogle Scholar
  30. 30.
    Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345–8. doi: 10.1038/nature14282.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901–7. doi: 10.1038/bjc.2013.28.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. doi: 10.1186/1471-2407-13-78.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217–24. doi: 10.1245/s10434-011-1814-0.CrossRefPubMedGoogle Scholar
  34. 34.
    Luo YP, Zhou H, Krueger J, Kaplan C, Liao D, Markowitz D, et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene. 2010;29(5):662–73. doi: 10.1038/onc.2009.308.CrossRefPubMedGoogle Scholar
  35. 35.
    Wani N, Nasser MW, Ahirwar DK, Zhao H, Miao Z, Shilo K, et al. C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res. 2014;16(3):R54. doi: 10.1186/bcr3665.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol. 2014. doi: 10.1007/s10147-014-0672-8.PubMedGoogle Scholar
  37. 37.
    Jiang N, Deng JY, Liu Y, Ke B, Liu HG, Liang H. The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer. Biomarkers. 2014;19(6):444–51. doi: 10.3109/1354750X.2014.926567.CrossRefPubMedGoogle Scholar
  38. 38.
    Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55–9. doi: 10.4048/jbc.2013.16.1.55.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Yao M, Liu Y, Jin H, Liu X, Lv K, Wei H, et al. Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. OncoTargets Ther. 2014;7:1743–52. doi: 10.2147/OTT.S69657.Google Scholar
  40. 40.
    Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15:195. doi: 10.1186/s12885-015-1204-2.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002;347(20):1566–75. doi: 10.1056/NEJMoa021153.CrossRefPubMedGoogle Scholar
  42. 42.
    Mylona E, Tzelepis K, Theohari I, Giannopoulou I, Papadimitriou C, Nakopoulou L. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathology. 2013;62(3):472–80. doi: 10.1111/his.12013.CrossRefPubMedGoogle Scholar
  43. 43.
    Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, et al. ERbeta1: characterization, prognosis, and evaluation of treatment strategies in ERalpha-positive and -negative breast cancer. BMC Cancer. 2014;14:749. doi: 10.1186/1471-2407-14-749.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jin Hong
    • 1
  • Yan Mao
    • 2
  • Xiaosong Chen
    • 1
  • Li Zhu
    • 1
  • Jianrong He
    • 1
  • Weiguo Chen
    • 1
  • Yafen Li
    • 1
  • Lin Lin
    • 3
  • Xiaochun Fei
    • 4
  • Kunwei Shen
    • 1
  1. 1.Comprehensive Breast Health Center, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  2. 2.Center of Diagnosis and Treatment for Breast DiseaseAffiliated hospital of Qingdao UniversityQingdaoChina
  3. 3.Department of Clinical Laboratory, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina
  4. 4.Department of Pathology, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations